Invex Therapeutics Ltd (ASX: IXC) Share Price and News

Price

 

Movement

   

  (20 mins delayed)

52 Week Range

  -  

 
1 Year Return

 

Invex Therapeutics Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $6.76 million
P/E Ratio N/A
Dividend Yield 248.40%
Shares Outstanding 75.15 million
Earnings per share -0.080
Dividend per share 0.19
Year To Date Return -13.58%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range

-

Yesterday's Close

Today's Open

Days Range

-

Volume

Avg. Volume (1 month)

Turnover

as at 24 Feb 3:44pm

  • Invex Therapeutics Ltd (ASX: IXC)
    Latest News

    Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
    Share Gainers

    This ASX healthcare company just got FDA approval, and its share price is soaring 18%

    Invex Therapeutics is exciting the market today after announcing some big news.

    Read more »

    IXC ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size
    YesNo

    About Invex Therapeutics Ltd

    Invex Therapeutics Ltd is a biopharmaceutical company, focused on the repurposing of an already approved drug, Exenatide, for efficacious treatment of neurological conditions derived from or involving raised ICP including TBI, stroke and hydrocephalus. In addition, the Group has generated early-stage data on the use of Exenatide in the treatment of glaucoma, through the lowering of intraocular pressure in the eye. Geographically, it operates only in Australia.

    IXC Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    29 Oct 2024 $0.09 $0.00 0.00% 10,000 $0.09 $0.09 $0.09
    28 Oct 2024 $0.09 $0.01 12.99% 134,897 $0.09 $0.09 $0.09
    25 Oct 2024 $0.08 $-0.01 -12.20% 6,642 $0.08 $0.08 $0.08
    23 Oct 2024 $0.08 $0.00 0.00% 7,657 $0.08 $0.08 $0.08
    10 Oct 2024 $0.09 $0.00 0.00% 117,073 $0.08 $0.09 $0.08
    09 Oct 2024 $0.08 $0.00 0.00% 80,085 $0.08 $0.08 $0.08
    07 Oct 2024 $0.08 $0.00 0.00% 75,208 $0.08 $0.08 $0.08
    04 Oct 2024 $0.08 $0.00 0.00% 2,177 $0.08 $0.08 $0.08
    03 Oct 2024 $0.08 $0.00 0.00% 273,133 $0.08 $0.08 $0.08

    Director Transactions Data provided by Morningstar.

    Data provided by Morningstar.
    Date Director Type Amount Value Notes
    09 Apr 2024 Megan Baldwin Cancelled 400,000 $33,600
    As advised by the company. Cancellation of unlisted options
    27 Mar 2024 Thomas (Tom) Duthy Transfer 285,661 $21,424
    Off-market transfer.
    27 Mar 2024 Thomas (Tom) Duthy Transfer 285,661 $21,424
    Off-market transfer.
    10 Nov 2023 Megan Baldwin Cancelled 100,000 $22,500
    As advised by the company. Cancellation of unlisted options

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr David McAuliffe Non-Executive Director Mar 2019
    Mr McAuliffe is a company director and entrepreneur who has had over 24 years of experience, mostly in the international biotechnology field. During that time, he was involved in numerous capital raisings and in-licensing of technologies. He is a founder of several companies in Australia, France, and the United Kingdom, many of which have become public companies.
    Mrs Narelle Warren Chief Financial OfficerCompany Secretary Mar 2019
    Ms Warren has over twenty years of corporate advisory, financial management and company secretarial experience. Ms Warren has coordinated and assisted in corporate transactions, including acquisitions, divestments and raising funds via private and public equity markets.
    Mr David Colin Wheeler Non-Executive Director Nov 2023
    Mr Wheeler has more than 30 years of Senior Executive Management, Directorships, and Corporate Advisory experience. He is a foundation Director and Partner of Pathways Corporate a boutique Corporate Advisory firm that undertakes assignments on behalf of family offices, private clients, and ASX listed companies. David is a Fellow of the Australian Institute of Company Directors (FAICD). He is currently Non-Executive Chairman of Protean Energy Ltd, PVW Resources Ltd and Avira Resources Ltd and a Non-Executive Director of Ragnar Metals Ltd, Tyranna Resources Ltd, MOAB Ltd, Cycliq Group Ltd, Cradle Resources Ltd and OZZ Resources Ltd.
    Dr Thomas (Tom) Duthy Executive Director Oct 2020
    Dr Duthy has over 18 years of direct financial market and executive level/Board experience with ASX listed companies. He is a Director and Founder of Nemean Group, which provides corporate advisory and investor relations (IR) services in the Life Sciences and Technology sectors. Prior to Sirtex, Tom spent ten years as a leading sell-side Healthcare & Biotechnology analyst at Taylor Collison Limited, focused mainly on small cap companies.

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Minderoo Group Pty Ltd 5,000,000 6.65%
    Celtic Capital Pte Ltd <Investment 1 A/C> 4,450,000 5.92%
    Tattarang Pty Ltd <Forrest Fm Inv Peepingee A/C> 3,846,154 5.12%
    Tisia Nominees Pty Ltd <The Henderson Family A/C> 3,725,000 4.96%
    Mr Jason Loveridge 3,374,462 4.49%
    Mr David Jerimiah Mcauliffe <The Lazy D9M Investment A/C> 3,225,001 4.29%
    JK Nominees Pty Ltd <The Jk A/C> 2,750,000 3.66%
    Prof Alexandra Jean Sinclair 2,500,000 3.33%
    Sunset Capital Management Pty Ltd <Sunset Superfund A/C> 2,390,000 3.18%
    Mrs Kathryn Mary Salkilld 2,293,000 3.05%
    Bannaby Investments Pty Limited <Bannaby Super Fund A/C> 1,625,000 2.16%
    Porjed Pty Ltd <Deporj A/C> 1,600,000 1.13%
    Rock the Polo Pty Ltd <Rock The Polo A/C> 1,400,000 1.86%
    Oaktone Nominees Pty Ltd <The Grist Investment A/C> 1,338,518 1.78%
    Cityscape Asset Pty Ltd <Cityscape Family A/C> 1,150,000 1.53%
    Cabletime Pty Ltd <Ingodwe A/C> 1,120,000 1.49%
    Hammerhead Holdings Pty Ltd <HHH S/F A/C> 1,000,000 1.33%
    Mr Andrew Clayton <The King Carey A/C> 1,000,000 1.33%
    Mr Anthony De Nicola & Mrs Tanya Louise De Nicola De Nicola Family S/F A/C> 750,000 1.00%
    Endless Summer (Wa) Pty Ltd <Peter Nelson Super Fund A/C> 750,000 1.00%

    Profile

    since

    Note